Welcome to our dedicated page for Medical Mari news (Ticker: MJNA), a resource for investors and traders seeking the latest updates and insights on Medical Mari stock.
Medical Marijuana Inc. (MJNA) maintains its position as a pioneer in cannabis research and CBD product development. This comprehensive news hub provides investors and industry stakeholders with timely updates on corporate milestones, regulatory compliance developments, and scientific advancements.
Access verified information about MJNA's financial performance, strategic partnerships, and product innovations in one centralized location. The curated collection includes earnings reports, operational updates, and analysis of market trends impacting the CBD sector.
Key updates cover new product launches, research collaborations, manufacturing expansions, and compliance with evolving cannabis regulations. Users benefit from organized access to both corporate announcements and third-party analyses of MJNA's market position.
Bookmark this page for streamlined monitoring of MJNA's industry leadership in developing premium CBD products through rigorous quality standards and scientific partnerships.
Medical Marijuana, Inc. (MJNA) announces that its subsidiary, HempMeds®, supports Mexico's Chamber of Deputies in approving a bill for federal marijuana legalization. CEO Raúl Elizalde emphasizes the importance of regulating non-psychoactive cannabis derivatives. Elizalde, a prominent advocate for cannabis in Mexico, has previously fought for access to CBD for his daughter. Dr. Stuart Titus, MJNA CEO, highlights his efforts in legalizing CBD across Latin America and points to the failed black market as a key reason for legalization efforts. The company's international presence strengthens its market position.
Medical Marijuana, Inc. (MJNA) announced that its subsidiary, Kannaway®, achieved record sales in February 2021, marking its best month in company history. Since entering the Japanese market in late 2019, Kannaway® has expanded its footprint, offering high-quality cannabidiol (CBD) products. The global CBD oil market is projected to reach $5.3 billion by 2025, with significant growth expected in Asia-Pacific. CEO Blake Schroeder and Japan Division GM Peter Dale highlighted the positive consumer response and ongoing growth potential, reinforcing their commitment to the market.
Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary Kannaway® has received the Certified Drug Free approval from the Banned Substances Control Group (BSCG) for its Pure Gold CBD product. This certification ensures the product is free from substances banned by the US Anti-Doping Agency, providing assurance to athletes and consumers. The rigorous BSCG certification process includes toxicology reviews and random testing, enhancing consumer trust in the product's quality and safety.
Medical Marijuana, Inc. (OTC: MJNA) announced its subsidiary, Kannaway®, has submitted a Novel Foods application for its CBD products to the UK’s Food Standards Agency (FSA). This move is part of a broader effort to ensure free access to CBD-based products in Europe, following the establishment of the EIHA Novel Food Consortium. CEO Dr. Stuart Titus emphasized the growing demand for CBD and the ongoing regulatory discussions in the U.S. and UK that aim to facilitate its acceptance as a dietary supplement.
Medical Marijuana, Inc. (MJNA) highlights its involvement in Mexico’s emerging cannabis market following Raul Elizalde’s feature in a recent Reuters article. The piece discusses new legislation that may legalize both medicinal and recreational cannabis in Mexico, with MJNA's subsidiary HempMeds® positioned as a key player. The company has been selling CBD products in Mexico since 2016, being the first to import CBD under federal permit. CEO Dr. Stuart Titus expresses optimism about market growth in the coming months as U.S. and Canadian firms look to enter.
Medical Marijuana, Inc. (OTC: MJNA) announces that its investment partner AXIM® Biotechnologies has filed a provisional patent for a revolutionary face mask that captures and deactivates SARS-CoV-2. This innovation meets the surging demand for protective gear during the COVID-19 pandemic, with the market expected to reach $21.2 billion by 2026. The mask's proprietary reagents enhance protection by capturing the virus on contact, potentially overcoming limitations of traditional masks. AXIM is currently exploring regulatory pathways for U.S. and EU distribution.
Medical Marijuana, Inc. (OTC: MJNA) announced a significant milestone: its THC-free cannabidiol oil product, Real Scientific Hemp Oil-X™ (RSHO-X™), has passed a two-year stability test in compliance with FDA/ICH guidelines. The study, conducted by a certified Contract Research Organization, confirmed RSHO-X™ maintained its CBD concentration and stability under various environmental conditions. CEO Dr. Stuart Titus hailed it as a gold standard for the CBD industry, emphasizing the importance of product testing for legitimization.
